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For Peru, the incidence rate for tuberculosis (TB) in 2012 was 95/100,000 population, from which 0.3% were new cases of extensively drug-resistant (XDR) TB. 94% of these cases were from Lima ([@B1]). XDR-TB strains are resistant to isoniazid (INH), rifampicin (RIF), fluoroquinolones (FLQ), and at least one of the three injectable anti-TB drugs: amikacin (AMK), capreomycin (CAP), or kanamycin (KAN) ([@B2]). In 1999, Peru reported one case with this resistant pattern. However, the concept of XDR-TB appears in 2006 with the first outbreak in KwaZulu-Natal (KZN), South Africa ([@B3]).

In our quest to identify new possible mutations that can confer resistance in XDR-TB strains, we analyzed the XDR strain, INS-XDR, isolated from a Peruvian patient with active tuberculosis. We determined the strain's lineage to be Latin American--Mediterranean (LAM) using 24 mycobacterial interspersed repetitive unit-variable number of tandem repeat (MIRU-VNTR) loci ([@B4]) and SpolPred ([@B5]). The genomic DNA was sequenced on an Illumina HiSeq 2000 with 1,140× coverage. Sequence reads for the isolates were mapped against the corrected reference genome *M. tuberculosis* strain H37Rv The average coverage was 82 for INS-XDR (49,793,402 mapped reads) and assembly with BWA v0.5.9-r16 ([@B6]), using H37Rv genome (AL123456.3) ([@B7]) as a reference. For annotation process, we used Rapid Annotations using Subsystem Technology ([@B8]) and the Prokaryotic Genome Annotation Pipeline. The sequencing data generated has 49,793,402 paired-ends reads. The assembling process resulted in 20 contigs that represents 99.98% of the H37Rv genome. The INS-XDR has a total of 4,391,020 pb with an average G+C content of 65.4%. We used Sanger sequencing to confirm specific mutations. Phenotypically, this strain was resistant to RIF, INH, FLQ, KAN, and CAP. However, sequence analysis of *rrs* and the promoter *eis* do not show mutations for aminoglycosides resistance ([@B9]).

To analyze possible mutations causing resistance to CAP and KAN, a polymorphism study was carried out by comparing INS-XDR against KZN605 (a XDR-TB strain of LAM linage) and 16 reported TB-XDR genomes from China, FJ05194, GuangZ0019 ([@B10]), XDR1219, XDR1221 ([@B11]), GuangZ0008, 293, FJ07070, GuangZ0017, GuangZ0026 ([@B12]); Peru, Peru_04_R0292, Peru_03_R0268 ([@B13]); Russia, CTRI-4 ([@B14]), Russia_03-R1082 ([@B13]); Malaysia, UM1072388579 ([@B15]), and South Africa, KZN_R506 ([@B16]) and KZN_605. Single nucleotide polymorphisms (SNPs) were identified using SNPsFinder ([@B17]) and SNP tree ([@B18]), and were classified in the Clusters of Orthologous Groups (COG) database ([@B19]). These analyses showed evidence of 218 non-synonymous SNPs mainly in four COGs: (1) replication, recombination and repair, L, *n*=14, (2) energy production and conversion, C, *n*=14, (3) amino acid transport and metabolism, E, *n*=12, and (4) secondary metabolites biosynthesis, transport, and catabolism, Q, *n*=11. These 218 non-synonymous SNPs belong to 125 genes. Given that CAP and KAN act by inhibiting protein synthesis and causing production of abnormal proteins, we hypothesize that the 14 non-synonymous SNPs belonging to the C category would be the principal SNPs responsible for CAP and KAN resistance. This provides evidence that it may be worthwhile to explore these new SNPs for diagnosis of XDR-TB.
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This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession [JANH00000000](JANH00000000). The version described in this paper is version JANH01000000.
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